SCIENTIFIC publications

/cun/en/investigacion/publicaciones-cientificas/areaMain/02
  • Functional Relationship between Leptin and Nitric Oxide in Metabolism

    Becerril S (1,2,3), Rodríguez A (4,5,6), Catalán V (7,8,9), Ramírez B (10,11,12), Unamuno X (13,14,15), Portincasa P (16), Gómez-Ambrosi J (17,18,19), Frühbeck G (20,21,22,23).

    (1) Metabolic Research Laboratory, Clínica Universidad de Navarra, 31008 Pamplona, Spain.
    (2) CIBER Fisiopatología de la Obesidad y Nutrición (CIBEROBN), Instituto de Salud Carlos III, 31008 Pamplona, Spain.
    (3) Obesity and Adipobiology Group, Instituto de Investigación Sanitaria de Navarra (IdiSNA), 31008 Pamplona, Spain.
    (4) Metabolic Research Laboratory, Clínica Universidad de Navarra, 31008 Pamplona, Spain.
    (5) CIBER Fisiopatología de la Obesidad y Nutrición (CIBEROBN), Instituto de Salud Carlos III, 31008 Pamplona, Spain.
    (6) Obesity and Adipobiology Group, Instituto de Investigación Sanitaria de Navarra (IdiSNA), 31008 Pamplona, Spain.
    (7) Metabolic Research Laboratory, Clínica Universidad de Navarra, 31008 Pamplona, Spain.
    (8) CIBER Fisiopatología de la Obesidad y Nutrición (CIBEROBN), Instituto de Salud Carlos III, 31008 Pamplona, Spain.
    (9) Obesity and Adipobiology Group, Instituto de Investigación Sanitaria de Navarra (IdiSNA), 31008 Pamplona, Spain.
    (10) Metabolic Research Laboratory, Clínica Universidad de Navarra, 31008 Pamplona, Spain.
    (11) CIBER Fisiopatología de la Obesidad y Nutrición (CIBEROBN), Instituto de Salud Carlos III, 31008 Pamplona, Spain.
    (12) Obesity and Adipobiology Group, Instituto de Investigación Sanitaria de Navarra (IdiSNA), 31008 Pamplona, Spain.
    (13) Metabolic Research Laboratory, Clínica Universidad de Navarra, 31008 Pamplona, Spain.
    (14) CIBER Fisiopatología de la Obesidad y Nutrición (CIBEROBN), Instituto de Salud Carlos III, 31008 Pamplona, Spain.
    (15) Medical Engineering Laboratory, University of Navarra, 31008 Pamplona, Spain.
    (16) Clinica Medica "A. Murri", Department of Biomedical Sciences and Human Oncology, University of Bari Medical School, Policlinico Hospital, 70124 Bari, Italy.
    (17) Metabolic Research Laboratory, Clínica Universidad de Navarra, 31008 Pamplona, Spain.
    (18) CIBER Fisiopatología de la Obesidad y Nutrición (CIBEROBN), Instituto de Salud Carlos III, 31008 Pamplona, Spain.
    (19) Obesity and Adipobiology Group, Instituto de Investigación Sanitaria de Navarra (IdiSNA), 31008 Pamplona, Spain.
    (20) Metabolic Research Laboratory, Clínica Universidad de Navarra, 31008 Pamplona, Spain.
    (21) CIBER Fisiopatología de la Obesidad y Nutrición (CIBEROBN), Instituto de Salud Carlos III, 31008 Pamplona, Spain.
    (22) Obesity and Adipobiology Group, Instituto de Investigación Sanitaria de Navarra (IdiSNA), 31008 Pamplona, Spain.
    (23) Department of Endocrinology & Nutrition, Clínica Universidad de Navarra, 31008 Pamplona, Spain.

    Nutrients 06 SEPTEMBER 2019

  • Feasibility of transaortic approach to map an atrial re-entrant tachycardia within the pulmonary venous atrium in a patient with d-transposition of the great arteries after Mustard operation by using a high-density mini-basket catheter

    Solimene F (1), Maddaluno F (2), Schillaci V (1), García-Bolao I (3).

    (1)Department of Electrophysiology, Clinica Montevergine, Mercogliano, Italy.
    (2) Boston Scientific, Italy.
    (3) Department of Cardiology and Cardiac Surgery, Clínica Universidad de Navarra, Pamplona, Spain.

    Journal of Cardiovascular Electrophysiology 26 AUGUST 2019

  • Final results from GCIG/ENGOT/AGO-OVAR 12, a randomised placebo-controlled phase III trial of nintedanib combined with chemotherapy for newly diagnosed advanced ovarian cancer

    Ray-Coquard I (1), Cibula D (2), Mirza MR (3), Reuss A (4), Ricci C (5), Colombo N (6), Koch H (7), Goffin F (8), González-Martin A (9), Ottevanger PB 10, Baumann K (11), Bjørge L (12), Lesoin A (13), Burges A (14), Rosenberg P (15), Gropp-Meier M (16), Harrela M (17), Harter P (18), Frenel JS (19), Minarik T (20), Pisano C (21), Hasenburg A (22), Merger M (23), du Bois A (18); AGO Study Group-led GCIG/ENGOT Intergroup Consortium.

    (1) GINECO and Medical Oncology Department, Centre Léon Bérard, University Claude Bernard Lyon, Lyon, France.
    (2) AGO and Oncogynecologic Center, Department of Obstetrics and Gynecology, General Faculty Hospital, Charles University of Prague, Prague, Czech Republic.
    (3) NSGO and Department of Oncology, Rigshospitalet Copenhagen University Hospital, Copenhagen, Denmark.
    (4) AGO and Coordinating Center for Clinical Trials, Philipps-University of Marburg, Marburg, Germany.
    (5) MITO and Division of Gynecologic Oncology, Department of Women and Children's Health and Public Health, Fondazione Policlinico Gemelli IRCCS, Rome, Italy.
    (6) MaNGO and European Institute of Oncology and University of Milan Bicocca, Milan, Italy.
    (7) AGO Austria and Department of Obstetrics and Gynecology, Paracelsus Medical University, Salzburg, Austria.
    (8) BGOG and CHU de Liège, University of Liège, Liège, Belgium.
    (9) GEICO and Medical Oncology Department, Clínica Universidad de Navarra, Madrid, Spain.
    (10) DGOG and Department of Medical Oncology, Radboud University Medical Centre, Nijmegen, The Netherlands.
    (11) AGO and Department of Gynecology, Klinikum der Stadt Ludwigshafen GmbH, Ludwigshafen, Germany.
    (12) NSGO and Department of Gynecology, Haukeland Universitetssykehus, Bergen, and Center for Cancer Biomarkers CCBIO, Department of Clinical Science, University of Bergen, Bergen, Norway.
    (13) GINECO and Department of Gynecologic Cancer and Medical Oncology, Centre Oscar Lambret, Lille, France.
    (14) AGO and Department of Obstetrics and Gynecology, University Hospital, LMU Munich, Germany.
    (15) NSGO and Department of Oncology, University Hospital Linköping, Linköping, Sweden.
    (16) AGO and Department of Gynecology and Obstetrics, Oberschwabenklinik, Krankenhaus St. Elisabeth, Ravensburg, Germany.
    (17) NSGO and Department of Gynoncology and Gynecology and Obstetrics, Kymenlaakso Central Hospital, Kotka, Finland.
    (18) AGO and Department of Gynecology and Gynecologic Oncology, Kliniken Essen Mitte, Essen, Germany.
    (19)GINECO and Centre René Gauducheau, Institut de Cancerologie de l'Ouest, Saint Herblain, France.
    (20) NSGO and National Institute of Oncology, Bratislava, Slovakia.
    (21) MITO and Department of Uro-Gynecologic Oncology, Istituto Nazionale per Io Studio e la Cura dei Tumori 'Fondazione G. Pascale' IRCCS, Napoli, Italy.
    (22) AGO and Department of Obstetrics and Gynecology, University Medical Center, Mainz, Germany.
    (23) Oncology Medicine, Boehringer Ingelheim International GmbH, Biberach, Germany.

    International Journal of Cancer 05 AUGUST 2019

  • Factors related to early castration resistance in metastatic prostate cancer. Results from the National Prostate Cancer Registry in Spain

    Lloret-Durá MA (1), Panach-Navarrete J (2), Martínez-Jabaloyas JM (2), Valls-González L (2), Cózar-Olmo JM (3), Miñana-López B (4), Gómez-Veiga F (5), Rodríguez-Antolín A (6); Grupo Español de Cáncer de Próstata.

    (1) Servicio de Urología, Hospital Clínico Universitario de Valencia, Facultat de Medicina i Odontologia, Universitat de València, Valencia, España.
    (2) Servicio de Urología, Hospital Clínico Universitario de Valencia, Facultat de Medicina i Odontologia, Universitat de València, Valencia, España.
    (3) Servicio de Urología, Hospital Virgen de las Nieves, Granada, España.
    (4) Servicio de Urología, Clínica Universidad de Navarra, Pamplona, España.
    (5) Servicio de Urología, C.H.U.A.C., Hospital Universitario de Salamanca, Salamanca, España.
    (6) Servicio de Urología, Hospital Gregorio Marañón, Madrid, España.

    Actas Urológicas Españolas 10 JULY 2019

  • Floppy Closing Door Epiglottis Treated Successfully with an Mhealth Application Based on Myofunctional Therapy

    O'Connor Reina C (1), Plaza Mayor G (2), Ignacio-Garcia JM (3), Baptista Jardin P (4), Garcia-Iriarte MT (5), Casado-Morente JC (1).

    (1) Chief of Department of Otorhinolaryngology, Hospital Quiron Salud Marbella, Hospital Quiron Salud Campo de Gibraltar, Cádiz, Spain.
    (2) Chief of Department of Otorhinolaryngology, Hospital Sanitas La Zarzuela, Hospital Universitario Fuenlabrada, Fuenlabrada, Spain.
    (3) Chief of Neumology Department, Hospital Quiron Salud Marbella, Hospital Quiron Salud Campo de Gibraltar, Cádiz, Spain.
    (4) Otorhinolaryngology Department, Clinica Universitaria de Navarra, Navarra, Spain.
    (5) Otorhinolaryngology Department, Hospital La Merced, Osuna, Sevilla, Spain.

    Case Reports in Otolaryngology 01 JULY 2019

you mayBE INTERESTED

WHAT TECHNOLOGY
DO WE USE?

The Clínica is the greater private hospital with technological equipment of Spain, all in a single center.

Imagen de un PET, tecnología de vanguardia en la Clínica Universidad de Navarra

OUR
PROFESSIONALS

The professionals of the Clínica perform continuous research and training, always to the benefit of the patient.

Imagen profesionales de la Clínica Universidad de Navarra

WHY CHOOSE
THE CLINICA?

Learn why we are different from other healthcare centers. Quality, speed, comfort and results.

Imagen del edificio de la Clínica Universidad de Navarra